C-reactive protein and systemic lupus erythematosus

Arthritis Care and Research

Volumn 59, Issue 12, 2008, Pages 1814-1820

  Gaitonde, Shilpa ^a   Samols, David ^a   Kushner, Irving ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CYTOKINE; INTERFERON; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; STAT1 PROTEIN; STAT3 PROTEIN;

HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; PATHOGENICITY; PLASMA CLEARANCE; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 57149110049     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24316     Document Type: Review

References (107)

1. Hill AG. C-reactive protein in the chronic rheumatic diseases. Lancet 1951;2:807-11.
2. Honig S, Gorevic P, Weissmann G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 1977;20:1065-70.
3. Becker GJ, Waldburger M, Hughes GR, Pepys MB. Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 1980;39:50-2.
4. Pereira Da Silva JA, Elkon KB, Hughes GR, Dyck RF, Pepys MB. C-reactive protein levels in systemic lupus erythematosus: a classification criterion? Arthritis Rheum 1980;23:770-1.
5. Ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642-8.
6. Bravo MG, Alarcon-Segovia D. C-reactive protein in the differential diagnosis between infection and disease reactivation in SLE. J Rheumatol 1981;8:291-4.
7. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta 1981;117:13-23.
8. Boekholdt SM, Hack CE, Sandhu MS, Luben R, Bingham SA, Wareham NJ, et al. C-reactive protein levels and coronary artery disease incidence and mortality in apparently healthy men and women: the EPIC-Norfolk prospective population study 1993-2003. Atherosclerosis 2006;187:415-22.
9. Woloshin S, Schwartz LM. Distribution of C-reactive protein values in the United States. N Engl J Med 2005;352:1611-3.
10. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006;119:166.e17-28.
11. Morley JJ, Kushner I. Serum C-reactive protein levels in disease. Ann N Y Acad Sci 1982;389:406-18.
12. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997;43:52-8.
13. Dhingra R, Gona P, Nam BH, D'Agostino RB Sr, Wilson PW, Benjamin EJ, et al. C-reactive protein, inflammatory conditions, and cardiovascular disease risk. Am J Med 2007;120:1054-62.
14. Barnes EV, Narain S, Naranjo A, Shuster J, Segal MS, Sobel ES, et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 2005;14:576-82.
15. Williams RC Jr, Harmon ME, Burlingame R, Du Clos TW. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 2005;32:454-61.
16. Spronk PE, ter Borg EJ, Kallenberg CG. Patients with systemic lupus erythematosus and Jaccoud's arthropathy: a clinical subset with an increased C reactive protein response? Ann Rheum Dis 1992;51:358-61.
17. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al, for the Leflunomide Rheumatoid Arthritis Investigators Group. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999;159:2542-50.
18. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum 2007;56:3919-27.
19. Bertouch JV, Roberts-Thompson PJ, Feng PH, Bradley J. C-reactive protein and serological indices of disease activity in systemic lupus erythematosus. Ann Rheum Dis 1983;42:655-8.
20. Zein N, Ganuza C, Kushner I. Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum 1979;22:7-12.
21. Moutsopoulos HM, Mavridis AK, Acritidis NC, Avgerinos PC. High C-reactive protein response in lupus polyarthritis. Clin Exp Rheumatol 1983;1:53-5.
22. Hinckley MJ, Dugowson CE, Wener MH. Inflammatory markers in systemic lupus erythematosus (SLE): two patterns of correlation between C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) [abstract]. Arthritis Rheum 2005;52 Suppl 9:S180-1.
23. Liou LB. Different monocyte reaction patterns in newly diagnosed, untreated rheumatoid arthritis and lupus patients probably confer disparate C-reactive protein levels. Clin Exp Rheumatol 2003;21:437-44.
24. Capper ER, Maskill JK, Gordon C, Blakemore AI. Interleukin (IL)-10, IL-1ra and IL-12 profiles in active and quiescent systemic lupus erythematosus: could longitudinal studies reveal patient subgroups of differing pathology? Clin Exp Immunol 2004;138:348-56.
25. Vila LM, Alarcon GS, McGwin G Jr, Bastian HM, Fessler BJ, Reveille JD, for the LUMINA Study Group. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol 2005;32:2150-5.
26. De Beer FC, Mallya RK, Fagan EA, Lanham JG, Hughes GR, Pepys MB. Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis. Lancet 1982;2:231-4.
27. Maury CP, Teppo AM, Wegelius O. Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann Rheum Dis 1982;41:268-71.
28. Meijer C, Huysen V, Smeenk RT, Swaak AJ. Profiles of cytokines (TNF α and IL-6) and acute phase proteins (CRP and α 1AG) related to the disease course in patients with systemic lupus erythematosus. Lupus 1993;2:359-65.
29. Ames PR, Alves J, Pap AF, Ramos P, Khamashta MA, Hughes GR. Fibrinogen in systemic lupus erythematosus: more than an acute phase reactant? J Rheumatol 2000;27:1190-5.
30. Beyan E, Beyan C, Demirezer A, Ertugrul E, Uzuner A. The relationship between serum ferritin levels and disease activity in systemic lupus erythematosus. Scand J Rheumatol 2003;32:225-8.
31. Hesselink DA, Aarden LA, Swaak AJ. Profiles of the acute-phase reactants C-reactive protein and ferritin related to the disease course of patients with systemic lupus erythematosus. Scand J Rheumatol 2003;32:151-5.
32. Bell SA, Faust H, Schmid A, Meurer M. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 1998;113:327-32.
33. Figueredo MA, Rodriguez A, Ruiz-Yague M, Romero M, Fernandez-Cruz A, Gomez-de la Concha E, et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 2006;33:1980-6.
34. Sjowall C, Bengtsson AA, Sturfelt G, Skogh T. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 2004;6:R87-94.
35. Rosenau BJ, Schur PH. Antibodies to C reactive protein. Ann Rheum Dis 2006;65:674-6.
36. Sjowall C, Wettero J. Pathogenic implications for autoantibodies against C-reactive protein and other acute phase proteins. Clin Chim Acta 2007;378:13-23.
37. Smith AJ, Kyle V, Cawston TE, Hazleman BL. Isolation and analysis of immune complexes from sera of patients with polymyalgia rheumatica and giant cell arteritis. Ann Rheum Dis 1987;46:468-74.
38. Croce MV, Segal-Eiras A. Identification of acute-phase proteins (APP) in circulating immune complexes (CIC) in esophageal cancer patients' sera. Cancer Invest 1996;14:421-6.
39. Vigushin DM, Pepys MB, Hawkins PN. Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. J Clin Invest 1993;91:1351-7.
40. Kushner I, Rzewnicki D. The acute phase response. In: Snyderman R, Galin J, editors. Inflammation: basic principles and clinical correlates. Philadelphia: Lippincott Williams & Wilkins; 1999.
41. Castell JV, Gomez-Lechon MJ, David M, Andus T, Geiger T, Trullenque R, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242:237-9.
42. Kalabalikis P, Papazoglou K, Gouriotis D, Papadopoulos N, Kardara M, Papageorgiou F, et al. Correlation between serum IL-6 and CRP levels and severity of head injury in children. Intensive Care Med 1999;25:288-92.
43. Herrmann JL, Blanchard H, Brunengo P, Lagrange PH. TNF α, IL-1β and IL-6 plasma levels in neutropenic patients after onset of fever and correlation with the C-reactive protein (CRP) kinetic values. Infection 1994;22:309-15.
44. Panichi V, Migliori M, De Pietro S, Taccola D, Bianchi AM, Giovannini L, et al. C-reactive protein and interleukin-6 levels are related to renal function in predialytic chronic renal failure [published erratum appears in Nephron 2002;92:498]. Nephron 2002;91:594-600.
45. Danesh J, Kaptoge S, Mann AG, Sarwar N, Wood A, Angleman SB, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78.
46. Tackey E, Lipsky PE, Illei GG. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus 2004;13:339-43.
47. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus: a putative role in pathogenesis. J Immunol 1991;147:117-23.
48. Chun HY, Chung JW, Kim HA, Yun JM, Jeon JY, Ye YM, et al. Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 2007;27:461-6.
49. Gabay C, Roux-Lombard P, de Moerloose P, Dayer JM, Vischer T, Guerne PA. Absence of correlation between interleukin 6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis. J Rheumatol 1993;20:815-21.
50. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13:17-22.
51. Lacki JK, Samborski W, Mackiewicz SH. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins. Clin Rheumatol 1997;16:275-8.
52. Ganapathi MK, Rzewnicki D, Samols D, Jiang SL, Kushner I. Effect of combinations of cytokines and hormones on synthesis of serum amyloid A and C-reactive protein in Hep 3B cells. J Immunol 1991;147:1261-5.
53. Dellalibera-Joviliano R, Dos Reis ML, Cunha Fde Q, Donadi EA. Kinins and cytokines in plasma and cerebrospinal fluid of patients with neuropsychiatric lupus. J Rheumatol 2003;30:485-92.
54. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. Clin Exp Rheumatol 2001;19:515-23.
55. Voronov E, Dayan M, Zinger H, Gayvoronsky L, Lin JP, Iwakura Y, et al. IL-1 β-deficient mice are resistant to induction of experimental SLE. Eur Cytokine Netw 2006;17:109-16.
56. Aringer M, Smolen JS. Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus 2004;13:344-7.
57. Gabay C, Smith MF, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
58. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283-9.
59. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus: enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995;38:1055-9.
60. Llorente L, Richaud-Patin Y, Garcia-Padilla C, Claret E, Jakez-Ocampo J, Cardiel MH, et al. Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800.
61. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
62. Loyer P, Ilyin G, Abdel Razzak Z, Banchereau J, Dezier JF, Campion JP, et al. Interleukin 4 inhibits the production of some acute-phase proteins by human hepatocytes in primary culture. FEBS Lett 1993;336:215-20.
63. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006;65:209-15.
64. Taylor AW, Ku NO, Mortensen RF. Regulation of cytokine-induced human C-reactive protein production by transforming growth factor-β. J Immunol 1990;145:2507-13.
65. Ohtsuka K, Gray JD, Stimmler MM, Toro B, Horwitz DA. Decreased production of TGF-β by lymphocytes from patients with systemic lupus erythematosus. J Immunol 1998;160:2539-45.
66. Agrawal A, Cha-Molstad H, Samols D, Kushner I. Overexpressed nuclear factor-κB can participate in endogenous C-reactive protein induction, and enhances the effects of C/EBPβ and signal transducer and activator of transcription-3. Immunology 2003;108:539-47.
67. Voleti B, Agrawal A. Regulation of basal and induced expression of C-reactive protein through an overlapping element for OCT-1 and NF-κB on the proximal promoter. J Immunol 2005;175:3386-90.
68. Nishikawa T, Hagihara K, Serada S, Isobe T, Matsumura A, Song J, et al. Transcriptional complex formation of c-Fos, STAT3, and hepatocyte NF-1 α is essential for cytokine-driven C-reactive protein gene expression. J Immunol 2008;180:3492-501.
69. Wong HK, Kammer GM, Dennis G, Tsokos GC. Abnormal NF-κB activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol 1999;163:1682-9.
70. Kyttaris VC, Juang YT, Tenbrock K, Weinstein A, Tsokos GC. Cyclic adenosine 5′-monophosphate response element modulator is responsible for the decreased expression of c-fos and activator protein-1 binding in T cells from patients with systemic lupus erythematosus. J Immunol 2004;173:3557-63.
71. Shai R, Quismorio FP Jr, Li L, Kwon OJ, Morrison J, Wallace DJ, et al. Genome-wide screen for systemic lupus erythematosus susceptibility genes in multiplex families. Hum Mol Genet 1999;8:639-44.
72. Moser KL, Neas BR, Salmon JE, Yu H, Gray-McGuire C, Asundi N, et al. Genome scan of human systemic lupus erythematosus: evidence for linkage on chromosome 1q in African-American pedigrees. Proc Natl Acad Sci U S A 1998;95:14869-74.
73. Floyd-Smith G, Whitehead AS, Colten HR, Francke U. The human C-reactive protein gene (CRP) and serum amyloid P component gene (APCS) are located on the proximal long arm of chromosome 1. Immunogenetics 1986;24:171-6.
74. Russell AI, Cunninghame Graham DS, Shepherd C, Roberton CA, Whittaker J, Meeks J, et al. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 2004;13:137-47.
75. Jonsen A, Gunnarsson I, Gullstrand B, Svenungsson E, Bengtsson AA, Nived O, et al. Association between SLE nephritis and polymorphic variants of the CRP and FcγRIIIa genes. Rheumatology (Oxford) 2007;46:1417-21.
76. Edberg JC, Wu J, Langefeld CD, Brown EE, Marion MC, McGwin G Jr, et al. Genetic variation in the CRP promoter: association with systemic lupus erythematosus. Hum Mol Genet 2008;17:1147-55.
77. Gaipl US, Kuhn A, Sheriff A, Munoz LE, Franz S, Voll RE, et al. Clearance of apoptotic cells in human SLE. Curr Dir Autoimmun 2006;9:173-87.
78. Tax WJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int 1995;48:666-73.
79. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998;41:1241-50.
80. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997;390:350-1.
81. Ogden CA, Elkon KB. Role of complement and other innate immune mechanisms in the removal of apoptotic cells. Curr Dir Autoimmun 2006;9:120-42.
82. Mold C, Baca R, Du Clos TW. Serum amyloid P component and C-reactive protein opsonize apoptotic cells for phagocytosis through Fc receptors. J Autoimmun 2002;19:147-54.
83. Vogt B, Fuhrnrohr B, Muller R, Sheriff A. CRP and the disposal of dying cells: consequences for systemic lupus erythematosus and rheumatoid arthritis. Autoimmunity 2007;40:295-8.
84. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005;117:104-11.
85. Rodriguez W, Mold C, Marnell LL, Hutt J, Silverman GJ, Tran D, et al. Prevention and reversal of nephritis in MRL/lpr mice with a single injection of C-reactive protein. Arthritis Rheum 2006;54:325-35.
86. Rodriguez W, Mold C, Kataranovski M, Hutt J, Marnell LL, Du Clos TW. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 2005;52:642-50.
87. 1 mice expressing a human C-reactive protein transgene. Arthritis Rheum 2003;48:1602-11.
88. Szalai AJ. C-reactive protein (CRP) and autoimmune disease: facts and conjectures. Clin Dev Immunol 2004;11:221-6.
89. Szalai AJ, Nataf S, Hu XZ, Barnum SR. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 2002;168:5792-7.
90. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003;197:711-23.
91. Ronnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus [review]. Arthritis Rheum 2006;54:408-20.
92. Crow MK. Collaboration, genetic associations, and lupus erythematosus. N Engl J Med 2008;358:956-61.
93. Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007;13:59-68.
94. Gottenberg JE, Cagnard N, Lucchesi C, Letourneur F, Mistou S, Lazure T, et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren's syndrome [published erratum appears in Proc Natl Acad Sci U S A 2006;103:5242]. Proc Natl Acad Sci U S A 2006;103:2770-5.
95. Moutsopoulos HM, Elkon KB, Mavridis AK, Acritidis NC, Hughes GR, Pepys MB. Serum C-reactive protein in primary Sjögren's syndrome. Clin Exp Rheumatol 1983;1:57-8.
96. Gabay C, Gay-Croisier F, Roux-Lombard P, Meyer O, Maineti C, Guerne PA, et al. Elevated serum levels of interleukin-1 receptor antagonist in polymyositis/dermatomyositis: a biologic marker of disease activity with a possible role in the lack of acute-phase protein response. Arthritis Rheum 1994;37:1744-51.
97. Ito N, Kawata S, Tamura S, Kiso S, Tsushima H, Maeda Y, et al. Induction of interleukin-6 by interferon α and its abrogation by a serine protease inhibitor in patients with chronic hepatitis C. Hepatology 1996;23:669-75.
98. Kalabay L, Nemesanszky E, Csepregi A, Pusztay M, David K, Horvath G, et al. Paradoxical alteration of acute-phase protein levels in patients with chronic hepatitis C treated with IFN-α2b. Int Immunol 2004;16:51-4.
99. Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-α (IFN-α)? The acute phase response in patients treated with IFN-α-2b. Eur J Clin Invest 2002;32 Suppl 1:79-83.
100. Brassard DL, Grace MJ, Bordens RW. Interferon-α as an immunotherapeutic protein. J Leukoc Biol 2002;71:565-81.
101. Baynes RD, Bezwoda WR, Dajee D, Lamparelli RD, Bothwell TH. Effects of α-interferon on iron-related measurements in human subjects. S Afr Med J 1990;78:627-8.
102. Black S, Kushner I, Samols D. C-reactive protein. J Biol Chem 2004;279:48487-90.
103. Zhang D, Sun M, Samols D, Kushner I. STAT3 participates in transcriptional activation of the C-reactive protein gene by interleukin-6. J Biol Chem 1996;271:9503-9.
104. Descombes P, Schibler U. A liver-enriched transcriptional activator protein, LAP, and a transcriptional inhibitory protein, LIP, are translated from the same mRNA. Cell 1991;67:569-79.
105. Honda Y, Rogers L, Nakata K, Zhao BY, Pine R, Nakai Y, et al. Type I interferon induces inhibitory 16-kD CCAAT/enhancer binding protein (C/EBP)β, repressing the HIV-1 long terminal repeat in macrophages: pulmonary tuberculosis alters C/EBP expression, enhancing HIV-1 replication. J Exp Med 1998;188:1255-65.
106. Borden EC, Sen GC, Uze G, Silverman RH, Ransohoff RM, Foster GR, et al. Interferons at age 50: past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6:975-90.
107. Wang W, Edington HD, Rao UN, Jukic DM, Land SR, Ferrone S, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNα2b. Clin Cancer Res 2007;13:1523-31.